BZYR
Burzynski Research Institute, Inc.
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 58,252 |
Stock Information
| Shares Outstanding | 131.45M |
| Cash Equivalents | $2K |
| Net Income | $-1.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.05M |
| EPS (TTM) | $-0.01 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $989K |
| Income | $-1.29M |
| Book/sh | $-0.00 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.03 |
| Current Ratio | 0.03 |
Returns & Margins
| ROA | -54020.21% |
Ownership
| Insider Ownership | 81.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -8.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.02 |
| SMA200 | $0.03 |
| RSI | 36.36 |
| ATR | 0.0018 |
| Shares Float | 24.97M |
| Volatility | 0.27 |
| Rel Volume | 0.13 |
Performance History
| Week | -20.00% |
| Month | -38.46% |
| Quarter | -68.00% |
| 6 Months | -80.95% |
| YTD | -60.00% |
| Year | -74.19% |
| 3 Years | -89.61% |
| 5 Years | -77.14% |
| 10 Years | -93.28% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.01 | 2,500 |
| 2026-06-11 | $0.01 | 0 |
| 2026-06-10 | $0.01 | 1,700 |
| 2026-06-09 | $0.01 | 0 |
| 2026-06-08 | $0.01 | 97,400 |
| 2026-06-05 | $0.01 | 50,000 |
| 2026-06-04 | $0.01 | 36,100 |
| 2026-06-03 | $0.01 | 0 |
| 2026-06-02 | $0.01 | 74,400 |
| 2026-06-01 | $0.01 | 0 |
| 2026-05-29 | $0.01 | 0 |
| 2026-05-28 | $0.01 | 0 |
| 2026-05-27 | $0.01 | 45,000 |
| 2026-05-26 | $0.01 | 0 |
| 2026-05-22 | $0.01 | 0 |
| 2026-05-21 | $0.01 | 0 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 30,000 |
| 2026-05-18 | $0.02 | 0 |
| 2026-05-15 | $0.02 | 55,200 |
| 2026-05-14 | $0.01 | 0 |
| 2026-05-13 | $0.01 | 0 |
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
đ° Latest News
No news articles available at the moment. Check back later for updates on BZYR.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $1,386,207 | $1,335,431 | $916,292 | $976,656 |
| Operating Expense | $1,386,207 | $1,335,431 | $916,292 | $976,656 |
| General And Administrative Expense | $340,273 | $470,432 | $197,787 | $217,146 |
| Other Income Expense | - | - | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Normalized Income | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Net Income From Continuing And Discontinued Operation | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Total Operating Income As Reported | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Net Income Common Stockholders | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Net Income | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Net Income Including Noncontrolling Interests | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Net Income Continuous Operations | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Pretax Income | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Operating Income | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Basic EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| EBITDA (Bullshit earnings) | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| EBIT | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Diluted Average Shares | $131,448,444 | $131,448,444 | $131,448,444 | $131,448,444 |
| Basic Average Shares | $131,448,444 | $131,448,444 | $131,448,444 | $131,448,444 |
| Diluted NI Availto Com Stockholders | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
| Research And Development | $1,045,934 | $864,999 | $718,505 | $759,510 |
| Selling General And Administration | $340,273 | $470,432 | $197,787 | $217,146 |
| Other Gand A | $340,273 | $470,432 | $197,787 | $217,146 |
| Tax Provision | - | $0 | $0 | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Total Assets | $847 | $2,310 | $1,934 | $4,661 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $847 | $2,310 | $1,934 | $4,661 |
| Prepaid Assets | $0 | $1,000 | $1,000 | $1,279 |
| Cash Cash Equivalents And Short Term Investments | $847 | $1,310 | $934 | $3,382 |
| Cash And Cash Equivalents | $847 | $1,310 | $934 | $3,382 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,484 | $27,433 | $15,661 | $3,455 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $42,484 | $27,433 | $15,661 | $3,455 |
| Payables And Accrued Expenses | $42,484 | $27,433 | $15,661 | $3,455 |
| Payables | $17,017 | $9,010 | $12,570 | - |
| Accounts Payable | $17,017 | $9,010 | $12,570 | $0 |
| Equity | ||||
| Common Stock Equity | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Total Equity Gross Minority Interest | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Stockholders Equity | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Retained Earnings | $-129,476,413 | $-128,090,206 | $-126,754,775 | $-125,838,483 |
| Other | ||||
| Ordinary Shares Number | $131,448,444 | $131,448,444 | $131,448,444 | $131,448,444 |
| Share Issued | $131,448,444 | $131,448,444 | $131,448,444 | $131,448,444 |
| Tangible Book Value | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Invested Capital | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Working Capital | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Total Capitalization | $-41,637 | $-25,123 | $-13,727 | $1,206 |
| Additional Paid In Capital | $129,303,327 | $127,933,634 | $126,609,599 | $125,708,240 |
| Capital Stock | $131,449 | $131,449 | $131,449 | $131,449 |
| Common Stock | $131,449 | $131,449 | $131,449 | $131,449 |
| Current Accrued Expenses | $25,467 | $18,423 | $3,091 | $3,455 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-388,531 | $-523,780 | $-249,516 | $-325,098 |
| Operating Activities | ||||
| Operating Cash Flow | $-388,531 | $-523,780 | $-249,516 | $-325,098 |
| Cash Flow From Continuing Operating Activities | $-388,531 | $-523,780 | $-249,516 | $-325,098 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $388,068 | $524,156 | $247,068 | - |
| Financing Cash Flow | $388,068 | $524,156 | $247,068 | $328,418 |
| Cash Flow From Continuing Financing Activities | $388,068 | $524,156 | $247,068 | $328,418 |
| Net Common Stock Issuance | $388,068 | $524,156 | $247,068 | - |
| Common Stock Issuance | $388,068 | $524,156 | $247,068 | - |
| Net Other Financing Charges | - | - | $247,068 | $328,418 |
| Other | ||||
| End Cash Position | $847 | $1,310 | $934 | $3,382 |
| Beginning Cash Position | $1,310 | $934 | $3,382 | $62 |
| Changes In Cash | $-463 | $376 | $-2,448 | $3,320 |
| Change In Working Capital | $16,051 | $11,772 | $12,485 | $-43,729 |
| Change In Payables And Accrued Expense | $15,051 | $11,772 | $12,206 | $-43,344 |
| Change In Accrued Expense | $7,044 | $15,332 | $-364 | $-10,832 |
| Change In Payable | $8,007 | $-3,560 | $12,570 | $-32,512 |
| Change In Account Payable | $8,007 | $-3,560 | $12,570 | $-32,512 |
| Change In Prepaid Assets | $1,000 | $0 | $279 | $-385 |
| Other Non Cash Items | $981,625 | $799,879 | $654,291 | $695,287 |
| Net Income From Continuing Operations | $-1,386,207 | $-1,335,431 | $-916,292 | $-976,656 |
Fetched: 2026-02-02